In their study, the proportions of TIGIT+CD3+, TIGIT+CD4+, and TIGIT+CD8+ T cells in the peripheral blood of CRC patients were higher than in healthy donors, and these subsets were even more enriched in tumor tissue than in matched blood samples. This evidence concerns the gene CD4 and neoplasm.